Rocket Pharmaceuticals (RCKT) Assets Average (2016 - 2025)
Historic Assets Average for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $394.5 million.
- Rocket Pharmaceuticals' Assets Average fell 608.11% to $394.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $394.5 million, marking a year-over-year decrease of 608.11%. This contributed to the annual value of $547.0 million for FY2024, which is 215.6% down from last year.
- Rocket Pharmaceuticals' Assets Average amounted to $394.5 million in Q3 2025, which was down 608.11% from $446.0 million recorded in Q2 2025.
- In the past 5 years, Rocket Pharmaceuticals' Assets Average ranged from a high of $583.7 million in Q1 2021 and a low of $394.5 million during Q3 2025
- In the last 5 years, Rocket Pharmaceuticals' Assets Average had a median value of $488.3 million in 2023 and averaged $493.7 million.
- As far as peak fluctuations go, Rocket Pharmaceuticals' Assets Average surged by 5671.26% in 2021, and later crashed by 2091.79% in 2024.
- Rocket Pharmaceuticals' Assets Average (Quarter) stood at $513.6 million in 2021, then decreased by 5.66% to $484.5 million in 2022, then increased by 20.23% to $582.6 million in 2023, then dropped by 20.92% to $460.7 million in 2024, then dropped by 14.37% to $394.5 million in 2025.
- Its last three reported values are $394.5 million in Q3 2025, $446.0 million for Q2 2025, and $499.4 million during Q1 2025.